- Home
- ATOS vs CHMI Comparison
ATOS vs CHMI Comparison
Compare ATOS & CHMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- CHMI
- Stock Information
- Founded
- ATOS 2009
- CHMI 2012
- Country
- ATOS United States
- CHMI United States
- Employees
- ATOS N/A
- CHMI N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- CHMI Real Estate Investment Trusts
- Sector
- ATOS Health Care
- CHMI Real Estate
- Exchange
- ATOS Nasdaq
- CHMI Nasdaq
- Market Cap
- ATOS 112.5M
- CHMI 96.3M
- IPO Year
- ATOS 2012
- CHMI 2013
- Fundamental
- Price
- ATOS $0.86
- CHMI $2.98
- Analyst Decision
- ATOS Strong Buy
- CHMI Hold
- Analyst Count
- ATOS 4
- CHMI 2
- Target Price
- ATOS $6.17
- CHMI N/A
- AVG Volume (30 Days)
- ATOS 668.8K
- CHMI 170.2K
- Earning Date
- ATOS 05-13-2025
- CHMI 08-07-2025
- Dividend Yield
- ATOS N/A
- CHMI 20.13%
- EPS Growth
- ATOS N/A
- CHMI N/A
- EPS
- ATOS N/A
- CHMI N/A
- Revenue
- ATOS N/A
- CHMI $27,506,000.00
- Revenue This Year
- ATOS N/A
- CHMI N/A
- Revenue Next Year
- ATOS N/A
- CHMI $94.28
- P/E Ratio
- ATOS N/A
- CHMI N/A
- Revenue Growth
- ATOS N/A
- CHMI 19.59
- 52 Week Low
- ATOS $0.55
- CHMI $2.34
- 52 Week High
- ATOS $1.66
- CHMI $3.99
- Technical
- Relative Strength Index (RSI)
- ATOS 51.39
- CHMI 49.87
- Support Level
- ATOS $0.84
- CHMI $2.95
- Resistance Level
- ATOS $0.93
- CHMI $3.04
- Average True Range (ATR)
- ATOS 0.06
- CHMI 0.05
- MACD
- ATOS -0.00
- CHMI -0.00
- Stochastic Oscillator
- ATOS 66.40
- CHMI 45.45
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About CHMI Cherry Hill Mortgage Investment Corporation
Cherry Hill Mortgage Investment Corp operates as a real estate investment trust in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, primarily through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.